Ventures | eureKARE

Bioproduction

eureKING, the first European SPAC in healthcare dedicated tobiomanufacturing, announces the signature of a put option for thepotential acquisition of Skyepharma to build a new European bio-CDMO leader

The proposed transaction would represent the first cornerstone of eureKING’s project to pursue bolt-on acquisitions to add innovative companies from the fast growing biotherapies CDMO segment to its platform to create a bio-CDMO leader and which could result in additional transactions. These transactions may be announced before the completion of the proposed transaction.

May 30, 2023

Bioproduction

eureKING, the first European SPAC in healthcare dedicated to biomanufacturing, announces its intention to combine with Skyepharma to build a new European bio-CDMO leader

eureKING has a clear and identified roadmap to bolster Skyepharma’s technology platform to consolidate the highly fragmented European market in biomanufacturing capacity, such as state-of-the-art facilities to manufacture cell and gene therapies in Europe.

May 16, 2023

Press

eureKARE co-leads EUR 5 million seed investment in Biomemory which is advancing cutting-edge DNA-based data storage solutions

Biomemory, founded in 2021, is positioned at the crossroads of Biotechnology and IT and is a key player in the DNA data storage space. Its ambition is to help meet the climate challenge posed by data centers.

November 28, 2022

eureKARE supports eureKING in EUR 150 million listing of the first European healthcare SPAC dedicated to biomanufacturing

eureKARE announces the successful IPO on Euronext Paris of eureKING, the first European SPAC1 in healthcare dedicated to biomanufacturing that has been co-founded by eureKARE.

May 12, 2022

NovoBiome and Inserm form new collaboration to simulate human intestinal physiology

This collaboration aims to complete NovoBiome’s disruptive NovoSift® ex-vivo research and discovery platform to analyze the symbiotic relationship between the microbiota and the human intestine.

February 22, 2022

eureKARE participates in DNA Script’s $200 Million Series C Financing

January 4, 2022

DNA Script Closes $200 Million Series C Financing with Completion of Second Tranche

DNA Script, a pioneer in Enzymatic DNA Synthesis (EDS) for on-demand DNA printing, today announced the completion of its Series C financing, raising $200 million of new capital. With this latest financing, DNA Script has raised $315 million since the company was founded in 2014.

January 4, 2022

eureKARE invests in Gynov

November 26, 2021

eureKARE invests in Maat Phama as cornestone investor of its IPO on Euronext Paris

October 15, 2021

Stellate Therapeutics publishes positive results in PLOS ONE on Neuroprotective Properties of Lead Candidate STL-101

Stellate Therapeutics Inc. (“the Company”, “Stellate”), a global biotechnology company developing disease-modifying therapies based on molecules derived from the microbiome to treat neurological conditions, is pleased to announce the publication of data evaluating the efficacy of the Company’s microbiome-derived lead candidate, STL-101 (synthesized queuine) in in vitro experiments. The data, published in the peer-reviewed scientific journal PLOS ONE, demonstrate that STL-101 has neuroprotective properties.

September 1, 2021

Archives